DRMAW — Dermata Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1853816 ·
Last close
—
Market Cap
—
52W High
—
52W Low
—
ADV30
—
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -1,926,382 | -1,847,706 | 7,465,652 | 6,945,282 | 1,052,649 |
| Dec 2025 | 0 | — | -1,900,393 | -1,861,888 | 7,863,826 | 7,521,978 | 1,640,446 |
| Sep 2025 | 0 | — | -1,760,671 | -1,691,989 | 5,071,410 | 4,664,127 | 1,111,308 |
| Jun 2025 | 0 | — | -1,772,731 | -1,701,093 | 6,640,516 | 6,480,930 | 1,026,265 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-7,757,559
Investing CF
—
Financing CF
$12,117,967
CapEx
—
Dividends Paid
—
Buybacks
$-367
EPS Diluted TTM
—
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-73,233,896
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-7,773,598
Pretax Income TTM
$-7,558,557
Interest Exp TTM
—
Analysts
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -7,773,598 | -7,558,557 | 7,863,826 | 1,640,446 | — | -7,757,559 |
| Dec 2024 | 0 | -12,513,242 | -12,287,461 | 3,533,888 | 1,972,794 | — | -11,162,948 |
| Dec 2023 | 0 | -8,041,906 | -7,794,690 | 7,978,634 | 1,623,616 | — | -6,408,931 |
| Dec 2022 | 0 | -9,674,486 | -9,610,913 | 6,944,488 | 922,634 | — | -8,834,164 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $949.47B | $1064.74 | — |
| JNJ | JOHNSON & JOHNSON | $554.09B | $230.18 | — |
| ABBV | AbbVie Inc. | $376.54B | $213.12 | — |
| MRK | Merck & Co., Inc. | $295.69B | $119.72 | — |
| AZN | ASTRAZENECA PLC | $290.30B | $187.19 | — |
News headlines (Yahoo Finance, 1h cache)
Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the First Quarter 2026
2026-05-13 20:05 · Yahoo
Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Application of Dermal Fillers with its Bioneedle Delivery System
2026-04-02 12:30 · Yahoo
Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Year Ended 2025
2026-03-26 21:15 · Yahoo
Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results
2025-11-14 21:05 · Yahoo
Dermata Announces Acceptance of Patent Application for Next-Generation Acne Treatment by Australian Patent Office
2025-10-02 12:00 · Yahoo
Life Sciences Virtual Investor Forum: Presentations Now Available for Online Viewing
2025-09-18 12:35 · Yahoo
Dermata Therapeutics Announces Presentation of Abstract at the European Academy of Dermatology and Venereology Congress 2025
2025-09-17 05:00 · Yahoo
Life Science Virtual Investor Forum Agenda Announced for September 18th
2025-09-16 15:57 · Yahoo
Dermata Therapeutics to Present at the Life Sciences Virtual Investor Forum September 18th
2025-09-16 12:35 · Yahoo
Dermata Therapeutics Announces Strategic Pivot to Over-the-Counter Skin Care Treatments
2025-09-10 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.